Transfer of Manufacturing Responsibilities Sample Clauses

Transfer of Manufacturing Responsibilities. Transfer of manufacturing responsibilities from Amgen to Hyseq or to a Third Party manufacturer approved by Amgen pursuant to Section 6.7 of the Collaboration Agreement will take place according to Section 16.9(c) of the Collaboration Agreement.
AutoNDA by SimpleDocs
Transfer of Manufacturing Responsibilities. Lilly agrees to provide to Xxxxx or its designees, at no cost to Xxxxx except as otherwise provided in this Section 4.6, up to five hundred (500) hours of manufacturing transfer assistance to be used by Xxxxx prior to the third year anniversary of the Closing Date. Any transfer assistance provided by Lilly to Xxxxx in excess thereof shall be paid for by Xxxxx at the rate of $275 per hour. Lilly will have no obligation to provide assistance in excess of the required 500 hours, but will consider requests for assistance by Xxxxx in good faith. In all cases, Xxxxx agrees to pay Lilly for all reasonable travel, room and board expenses incurred by Lilly personnel in providing such assistance. Lilly will invoice Xxxxx on a monthly basis for the expenses incurred during the previous calendar month. Xxxxx will pay such invoices within thirty (30) days from the date of invoice, with such payments being made by Federal Reserve electronic wire transfer to an account designated by Lilly. Lilly's obligation pursuant to this Section 4.6 will cease or be suspended, as applicable, in the event this Manufacturing Agreement is terminated or suspended by Lilly in accordance with the provisions of this Agreement. In connection with the technology transfer contemplated in this Section 4.6, Lilly will only be required to provide Xxxxx or its designees with such documentation and technical assistance as is reasonably necessary to transfer the manufacturing of Product to Xxxxx or its designees.
Transfer of Manufacturing Responsibilities. (a) Additionally, (i) if this Agreement is terminated by BMS or Medarex, pursuant to Section 14.2 with respect to a Product or MDX-1379 (A) in its entirety or (B) with respect to one or more countries and (ii) if BMS is then responsible for the manufacture or supply of any such Product or MDX-1379 (or any component thereof) for any such terminated country(ies) in the Territory, BMS shall continue to supply such Product or MDX-1379 (or such component) to Medarex in the Territory with respect to clause (A), or for such country(ies) with respect to clause (B), and, in each case, at a supply price equal to [*****];† and provided further that if Medarex changes or modifies the applicable Specifications resulting in an increase in BMS’ Manufacturing Costs with respect to a Product, the [*****]). Such obligation shall continue from the effective date of such termination until such time as Medarex is able to secure an equivalent alternative commercial manufacturing source at a comparable price, take an assignment of, and assume the obligations under, BMS’ agreement with a Third Party manufacturer or enter into a direct agreement with any Third Party manufacturing such Product or MDX-1379 in the country(ies) in which BMS’ rights terminated, in each case provided that Medarex uses Diligent Efforts to take appropriate action in furtherance of the foregoing, and further provided that, subject to Section 14.4.2(b), in no event shall such supply obligation extend for more than [*****] after the effective date of such termination. In any such event, BMS shall, at the request of Medarex, use good faith efforts to assign to Medarex, and upon such assignment, Medarex shall assume, any such Third Party manufacturing agreement to Medarex in its entirety or with respect to one or more countries, as applicable, and cooperate with Medarex at Medarex’s request to facilitate any discussions between Medarex and any such Third Party manufacturer with respect to such assignment (and assumption) or the negotiation of any direct agreement with a Third Party manufacturer, provided that, (x) to the extent Medarex receives the benefit of any existing Third Party manufacturing agreement, Medarex shall be responsible for any payments to such Third Party manufacturers required to transfer such agreements to Medarex and (y) if Medarex requests that BMS terminate any such agreement with a Third Party manufacturer, Medarex shall be responsible for any resultant fees, penalties or damages based ...
Transfer of Manufacturing Responsibilities. Lilly agrees to provide at no cost to NEOSAN other than the expenses described below, up to one thousand (1,000) hours of assistance per year for each of the first and second Contract Years of this Manufacturing Agreement. NEOSAN agrees to pay Lilly promptly all reasonable travel, room and board expenses incurred by Lilly personnel in providing such assistance. Lilly will invoice NEOSAN on a monthly basis for the expenses incurred during the previous calendar month. NEOSAN will pay such invoices in accordance with Section 2.3, above, except that NEOSAN will not pay such invoices by wire transfer if so instructed by Lilly not to do so. Lilly's obligation pursuant to this Section 4.6 will cease in the event this Manufacturing Agreement is terminated by Lilly pursuant to Sections 8.2 or 8.3. In connection with the technology transfer contemplated in this Section 4.6, Lilly will only be required to provide NEOSAN with such documentation as is reasonably necessary to transfer the manufacturing of Product to NEOSAN or a Third Person.
Transfer of Manufacturing Responsibilities. Transfer of manufacturing responsibilities from Amgen to Nuvelo or to a Third Party manufacturer approved by Amgen pursuant to Section 6.7 of the Collaboration Agreement will take place according to Section 16.9(c) of the Collaboration Agreement and notwithstanding any other provision of the Collaboration Agreement, the parties will work together to establish a manufacturing transition plan within the scope and bounds set forth in the outline attached to this License Agreement as Exhibit D.
Transfer of Manufacturing Responsibilities 

Related to Transfer of Manufacturing Responsibilities

  • Development Responsibilities From and after the Effective Date, BMS shall assume sole responsibility for the Development of Compounds and Products in the Field in the Territory during the Term at its own cost and expense (including responsibility for all funding, resourcing and decision-making, subject to Sections 3.3 and 3.4), except with respect to the performance by Ambrx of the Research Program activities assigned to Ambrx pursuant to the Research Plan and as otherwise may be agreed upon by the Parties in writing. BMS, by itself or through its Affiliates and Sublicensees, shall use Diligent Efforts to Develop a Compound or Product in the Field in accordance with the Development Plan for the purpose of obtaining a Regulatory Approval in each Major Market. For clarity, it is understood and acknowledged that Diligent Efforts in the Development of Compounds and Products may include sequential implementation of Clinical Trials and/or intervals between Clinical Trials for data interpretation and clinical program planning and approval.

  • Monitoring Responsibilities The Custodian shall furnish annually to the Fund, during the month of June, information concerning the foreign sub-custodians employed by the Custodian. Such information shall be similar in kind and scope to that furnished to the Fund in connection with the initial approval of this Contract. In addition, the Custodian will promptly inform the Fund in the event that the Custodian learns of a material adverse change in the financial condition of a foreign sub-custodian or any material loss of the assets of the Fund or in the case of any foreign sub-custodian not the subject of an exemptive order from the Securities and Exchange Commission is notified by such foreign sub-custodian that there appears to be a substantial likelihood that its shareholders' equity will decline below $200 million (U.S. dollars or the equivalent thereof) or that its shareholders' equity has declined below $200 million (in each case computed in accordance with generally accepted U.S. accounting principles).

  • Specific Responsibilities In addition to its overall responsibility for monitoring and providing a forum to discuss and coordinate the Parties’ activities under this Agreement, the JSC shall in particular:

  • Regulatory Responsibilities Following the approval by the FDA of an ANDA, Xxxx shall be solely responsible, with Corium’s reasonable assistance, for maintaining the ANDA for the Product including any necessary periodic reporting requirements. Furthermore, Xxxx shall be responsible for all adverse event reporting as required by the Act. Xxxx agrees to perform these activities in conformance with cGMP, the ANDA specifications and the Act. Xxxx shall provide Corium with copies of all material correspondence from or to regulatory authorities in the Territory relating to the maintenance of the ANDA.

  • Transfer of Materials In the event Acceleron exercises its rights pursuant to Section 10.5.1, Celgene shall negotiate in good faith with Acceleron regarding Celgene transferring to Acceleron, at Acceleron’s cost, materials developed under this Agreement in the course of Developing and Commercializing Licensed Compounds or Licensed Products that are directly related to Licensed Compounds or Licensed Products to the extent provided in and in accordance with such agreement.

  • Manufacturing Rights Manufacturing Rights will be governed by Attachment 6.

  • Manufacturing Agreement Each of the Sellers (as applicable) shall have executed and delivered to the Buyer the Manufacturing Agreement with respect to the portion of the Business conducted at the applicable Facility.

  • Quality Agreement Each Party will comply with the terms of the Quality Agreement in the performance of its obligations hereunder including record retention, audits and inspections, change control, adverse events and product recall. The Parties will conduct periodic Product quality reviews in accordance with the terms of the Quality Agreement.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Commercialization Reports After the First Commercial Sale of a Licensed Product anywhere in the Territory, LICENSEE shall submit to Cornell semi-annual reports on or before each February 28 and August 31 of each year. Each report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar half-year and shall show:

Time is Money Join Law Insider Premium to draft better contracts faster.